Stock of the Day for November 27, 2024

Novo Nordisk A/S Stock Report

Novo Nordisk A/S
NVO 90-day performance NYSE:NVO Novo Nordisk A/S
Current Price
$50.29
-1.08 (-2.11%)
(As of 02:22 PM ET)
30 Day Performance
-9.43%
  
  
90 Day Performance
4.26%
  
 
1 Year Performance
-55.59%
  
  
Market Capitalization
$224.53B
P/E Ratio
13.82
Dividend Yield
1.63%

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes.

Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies.

Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.

NVO Company Calendar

AUG. 6, 2025
Last Earnings
AUG. 18, 2025
Ex-Dividend for 8/26 Dividend
AUG. 26, 2025
Dividend Payable
OCT. 30, 2025
Today
NOV. 5, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End

Recent Novo Nordisk A/S News

Novo Nordisk submits proposal to acquire Metsera, Inc.
Metsera Shares Leap Premarket as Novo Nordisk Looks to Outbid Pfizer
Novo Nordisk hijacks Pfizer with bid for US biotech Metsera
Novo Nordisk Offers $6.5 Billion for Metsera to Challenge Pfizer
This report was written by MarketBeat.com on October 30, 2025. This report first appeared on MarketBeat.com.